Skip to Main content Skip to Navigation
Journal articles

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

Abstract : Hepatocellular carcinoma (HCC) represents similar to 90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first-and second-line treatment. This study focused on the efficacy of antiangiogenics in patients with advanced HCC and particularly the rising role of ramucirumab in patients with elevated alpha-fetoprotein at diagnosis.
Document type :
Journal articles
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-02143684
Contributor : Ghislain Bidaut <>
Submitted on : Wednesday, May 29, 2019 - 2:53:27 PM
Last modification on : Thursday, May 30, 2019 - 1:38:44 AM

Links full text

Identifiers

Collections

Citation

Marine Gilabert, Jean-Luc Raoul. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. Journal of Hepatocellular Carcinoma, 2018, 5, pp.91-98. ⟨10.2147/JHC.S157413⟩. ⟨hal-02143684⟩

Share

Metrics